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Abstract
Aims/hypothesis Recent evidence suggests that reduced syn-
thesis of nitric oxide in endothelial cells, i.e. endothelial
dysfunction, contributes to the impaired action of insulin in the
vasculature of patients with type 2 diabetes. We investigated
whether selective inhibition of phosphodiesterase-5 by tadala-
fil has beneficial effects on peripheral microcirculation and
glucose uptake in these patients.
Methods We enrolled seven postmenopausal women with
type 2 diabetes and ten age-matched healthy women as
controls in a placebo-controlled study to evaluate the acute
metabolic effects of tadalafil. We performed microdialysis
and blood flow measurements in muscle, and sampled
arterial and deep venous blood before and after a single
dose of tadalafil 20 mg or placebo. Circulating glucose and
insulin levels, muscle capillary recruitment as reflected by
permeability surface area for glucose (PSglu) and forearm
glucose uptake were measured.
Results In women with type 2 diabetes, but not in the
control group, tadalafil induced increases in the incremental
AUC for PSglu (tadalafil vs placebo 41±11 vs 4±2 ml
[100 g]
−1 min
−1, p<0.05) and forearm glucose uptake (46±
9 vs 8±4 µmol [100 g]
−1 min
−1, p<0.05). The variable that
best predicted forearm glucose uptake was PSglu, which
explained 70% of its variance. However, fasting glucose
and insulin concentrations were similar following treatment
with placebo or tadalafil in the two groups.
Conclusions/interpretation This study suggests that tada-
lafil evokes positive metabolic effects in insulin-resistant
w o m e nw i t ht y p e2d i a b e t e s .
Keywords Glucose-lowering drugs.Endothelial
dysfunction.Insulin resistance.Microdialysis.
Phosphodiesterase-5
Abbreviations
ΔAUC AUC for the tadalafil vs placebo day
PDE-5 Phosphodiesterase-5
PSglu Permeability surface area for glucose
Introduction
Previous studies have shown strong associations between
microvascular dysfunction and insulin resistance [1, 2].
Recent evidence suggests that reduced synthesis of nitric
oxide in endothelial cells contributes to the impaired action
of insulin in the vasculature of patients with insulin
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DOI 10.1007/s00125-010-1819-4resistance syndrome [3]. A recent study of the pump-
perfused rat hindlimb showed that stimulation of nitric oxide
production by methacholine induced positive effects on
muscle metabolism [4], while we have previously demon-
strated beneficial effects of methacholine on capillary
recruitment and forearm glucose uptake in insulin-resistant
obese humans [5]. However, as methacholine cannot be used
therapeutically, alternative approaches would be required to
promote nitric oxide signalling. Nitric oxide promotes
vasorelaxation by increasing levels of cyclic guanosine
monophosphate, which is degraded by phosphodiesterase 5
(PDE-5). PDE-5 inhibition should thus result in an amplified
nitric oxide signal and improved vascular function. However,
little is known about the metabolic effects of PDE-5
inhibition in skeletal muscle. Here, we investigated whether
the selective PDE-5 inhibitor tadalafil improves muscle
capillary recruitment and forearm glucose uptake in post-
menopausal women with type 2 diabetes.
Methods
Study participants This study was conducted on seven
postmenopausal women with type 2 diabetes and ten age-
matched healthy women as controls. Men were not
included because of ethical concerns.
The type 2 diabetes women were eligible if they met the
following criteria: (1) age 55 to 65 years; (2) BMI 27 to
35 kg/m
2; (3) no tobacco use; (4) HbA1c 5% to 7.5%
(reference values 3.9% to 5.3%); (5) no significant
complications and concomitant metabolic disease as deter-
mined by medical history, physical examination and
screening laboratory evaluations; and (6) no ongoing
treatment with oestrogens, nitrates, beta-blockers or gluco-
corticoids.
The healthy controls were enrolled according to the
following criteria: (1) a healthy state as determined by
medical history, physical examination and screening labo-
ratory evaluations; (2) BMI 18 to 25 kg/m
2; (3) normal
glucose tolerance during a 75 g oral glucose tolerance test;
(4) no current use of oestrogen or other regular medica-
tions; and (5) no tobacco use.
Clinical characteristics of the participants are shown in
Table 1. All participants gave written informed consent and
the study protocols were approved by the Ethics Committee
at the University of Gothenburg, Sweden.
Study procedures After an overnight fast, the investigation
started at 08:00 hours with participants lying supine in a
room kept at 27°C. The type 2 diabetes women did not take
their usual medication (except insulin) the evening before
and on the morning of the study day. Catheters were
inserted into a deep antecubital vein of the right forearm
and into the radial artery of the left arm for sampling of deep
venous and arterial blood, respectively; a catheter was
also inserted into a superficial vein of the left forearm for
blood sampling. Thereafter one mercury in-silastic strain
gauge was placed on the upper third of the right forearm
for blood flow measurements by plethysmography [5].
Muscle microdialysis for interstitial measurements of
glucose was performed as previously described [6].
Calibration of the catheters was performed using urea as
an internal reference.
Study protocol The study participants received either
placebo or 20 mg tadalafil orally on one occasion and the
opposite treatment after an interval of 4 to 6 weeks. From
1 h before tadalafil or placebo until 4 h after treatment
measurements were taken every 15 min (muscle dialysates)
or 30 min (blood flow and blood sampling). Baseline was
defined as the mean of the measurements taken in the 1 h
before administration of tadalafil or placebo. Samples
collected were immediately stored at −20°C until analysed.
Calculations We used substrate balance studies and the
equations of Fick and Renkin to estimate muscle
glucose uptake and capillary recruitment in response to
tadalafil in the fasting state [6, 7]. Permeability surface
area for glucose (PSglu) was calculated as described
previously [7].
Analytical methods Metabolite concentrations in dialy-
sates and plasma fractions were determined with a
colorimetric (glucose) and an ultraviolet (urea) method
on a microdialysis analyser (CMA 600; CMA Micro-
dialysis, Stockholm, Sweden). Serum insulin concentra-
tions were measured by an ultrasensitive insulin ELISA
(Mercodia, Uppsala, Sweden) with a detection limit of
0.4 pmol/l and intra-and interassay coefficients of
variation of 5.3% and 2.7%, respectively.
Table 1 Clinical characteristics of women participants
Control Type 2 diabetes p value
n 10 7
Age (years) 60±5 61±6 NS
BMI (kg/m
2) 22.7±1.0 29.5±3.4 0.0006
Waist circumference (cm) 82±5 100±12 0.002
Systolic BP (mmHg) 118±10 140±11 0.003
Diastolic BP (mmHg) 78±7 87±5 0.028
HbA1c (%)
a 4.4±0.1 5.5±0.8 0.0008
Plasma glucose (mmol/l) 4.7±0.3 7.0±1.2 0.0006
Serum insulin (pmol/l) 30±8 90±36 0.0006
Data presented as mean ± SD
aReference value 3.9–5.3%
2206 Diabetologia (2010) 53:2205–2208Statistical analysis Comparisons within and between the
groups were performed using two-way ANOVA for repeated
measures. AUC and incremental AUC were calculated by the
trapezoidal integration method. The correlation between pairs
of variables was assessed by a simple linear regression
analysis, while multivariate relationships were analysed using
a general linear model. Data are shown as mean ± SEM. A
two-sided p value of p<0.05 was considered statistically
significant. Statistical analyses were carried out using
software from StatView (Abacus Concepts, Berkeley, CA,
USA) and SAS Institute (Cary, NC, USA).
Results
Compared with placebo, tadalafil did not affect the incremen-
tal AUC for either PSglu or forearm glucose uptake in the
control group, but did promote increases in both of these
measurements in the type 2 diabetic women (Fig. 1a–d).
Tadalafil did not affect the incremental AUC for forearm
blood flow in any of the study groups (Fig. 1e–f).
The difference in AUC for the tadalafil vs placebo day
(ΔAUC) for PSglu correlated with ΔAUC for forearm
glucose uptake in the control group (r
2 0.74, p<0.01) and
in the type 2 diabetic women (r
2 0.89, p<0.01).
Multiple linear regression analysis showed that ΔAUC
PSglu was an independent predictor of forearm glucose
uptake and accounted for approximately 70% of its variance
(Electronic supplementary material [ESM] Table 1). Other
confounders measured did not substantially modify the
prediction by ΔAUC PSglu alone and only accounted for
additional 5% of variance (ESM Table 1).
No significant differences in serum insulin and plasma
glucose levels were shown at baseline, and at 2 and 4 h
following treatment with placebo or tadalafil in both study
groups (data not shown).
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Fig. 1 Incremental AUC for
PSglu (a, b), forearm glucose
uptake (c, d) and forearm blood
flow (e, f) in healthy controls
(a, c, e) and patients with type 2
diabetes (b, d, f) following
placebo (white circles/bars)
or tadalafil 20 mg (black circles/
bars). All negative incremental
AUC values were set to zero,
leaving means above zero in bar
graph insets. *p<0.05 compared
with placebo
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Our evaluation of the potential of PDE-5 inhibition to
improve peripheral microcirculation and metabolism in
women with type 2 diabetes showed that tadalafil increased
capillary recruitment and muscle glucose uptake in the
forearm of insulin-resistant humans. Our study is the first to
suggest that PDE-5 inhibition may be a novel approach to
improve glucose uptake in patients with type 2 diabetes.
Our current findings are in agreement with our previous
study, which showed increased capillary surface area and
glucose uptake in insulin-resistant obese patients following
methacholine infusion [5]. Interestingly, a recent study in
high-fat fed mice showed that chronic treatment with the
PDE-5 inhibitor sildenafil resulted in increased muscle
glucose uptake, but without activation of downstream
insulin signalling in the muscle extracts [8]. The authors
thus speculated that glucose uptake was facilitated by
improved capillary recruitment or by increased cyclic
guanosine monophosphate levels in skeletal muscle cells
[8]. This could plausibly explain our results, indicating that
a component of muscle glucose uptake is independent of
PSglu. In contrast to our findings, a recent study in women
with the metabolic syndrome showed an effect of tadalafil
on beta cell function, whereas insulin resistance as
measured by the minimal model was unchanged [9]. In
the absence of this test in the present study, one should
consider that positive effects of tadalafil on metabolism
may be mediated by effects on insulin secretion, insulin
sensitivity or both.
Our observation of a strong correlation between ΔAUC
PSglu and ΔAUC forearm glucose uptake in both study
groups is consistent with previous studies showing that a
microvascular response is critical for glucose uptake in
skeletal muscle [4, 10]. Thus, it is possible that increased
nutritive blood flow may enhance glucose delivery to
insulin-resistant muscle in the postabsorptive state, too.
Our multiple regression analysis showed that forearm blood
flow did not substantially affect the variance of forearm
glucose uptake. The results are in agreement with the
concept that muscle glucose uptake is more dependent on
capillary recruitment than on forearm blood flow in type 2
diabetes patients [6, 10].
The participants experienced some tadalafil-related side
effects such as myalgia, dyspepsia and nausea, but
hypotension was not observed. Chronic treatment with
low-dose tadalafil is not associated with tachyphylaxis or
serious side effects [11], indicating that it is a safe drug to
use.
In conclusion, this study implies that tadalafil has acute
positive effects on capillary recruitment and glucose uptake
in insulin-resistant skeletal muscle of type 2 diabetic women.
Asweinvestigatedtheresponsetotadalafilinthefastingstate,
further studies will be required to delineate whether PDE-5
inhibition has beneficial effects on the vasculature and beta
cell function after a meal, and on insulin sensitivity assessed
by glucose clamp in chronic studies.
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